HOLX - Hologic: Unfairly Punished Or Not? Examination Of Cash Flow And Earnings
- Hologic presents with the economics to withstand current macroeconomic crosscurrents currently plaguing equity markets.
- The company's stable cash flow and free cash conversion has built a solid underweight to the investment debate.
- We note potential mispricing as the company's top to bottom line fundamentals have curled up whilst the stock trades sideways.
- We are seeking a return objective of 31% with an exit at the $99–$100 level.
- Here we cover the relevant parts of the HOLX investment debate.
For further details see:
Hologic: Unfairly Punished, Or Not? Examination Of Cash Flow And Earnings